Taiho Ventures returned for a $72m series B round closed by Werewolf Therapeutics, which is now set to advance two lead oncology assets through phase 1 trials.

US-based cancer biotherapeutics developer Werewolf Therapeutics has completed a $72m series B round backed by Taiho Ventures, the corporate venturing arm of pharmaceutical firm Taiho Pharmaceutical.

Investment Manager RA Capital Management led the round, which included UPMC Enterprises, Deerfield Management, HBM Healthcare Investments, Soleus Capital, Adage Capital, Sphera Healthcare, CaaS Capital, MPM Capital, Longwood Fund, Arkin Bio Ventures and DC Investment Partners.

Werewolf is working on treatments to bolster the body’s immune response to cancer. They will…